{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:17:52Z","timestamp":1762899472473,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T00:00:00Z","timestamp":1505865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s11255-017-1703-y","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T04:26:02Z","timestamp":1505881562000},"page":"2143-2149","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1702-4127","authenticated-orcid":false,"given":"Michele","family":"Marchioni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raisa S.","family":"Pompe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhe","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cindolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Berardinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Schips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,9,20]]},"reference":[{"issue":"35","key":"1703_CR1","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2006.08.5415","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24(35):5601\u20135608. doi:\n                        10.1200\/JCO.2006.08.5415","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1703_CR2","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.21037\/tcr.2016.06.05","volume":"5","author":"PK Modi","year":"2016","unstructured":"Modi PK, Farber NJ, Singer EA (2016) Precision oncology: identifying predictive biomarkers for the treatment of metastatic renal cell carcinoma. Transl Cancer Res 5(Suppl 1):S76\u2013S80. doi:\n                        10.21037\/tcr.2016.06.05","journal-title":"Transl Cancer Res"},{"issue":"7","key":"1703_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):917\u2013927. doi:\n                        10.1016\/S1470-2045(16)30107-3","journal-title":"Lancet Oncol"},{"issue":"22","key":"1703_CR4","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271\u20132281. doi:\n                        10.1056\/NEJMoa066838","journal-title":"N Engl J Med"},{"issue":"19","key":"1703_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803\u20131813. doi:\n                        10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"5","key":"1703_CR6","doi-asserted-by":"publisher","first-page":"e63341","DOI":"10.1371\/journal.pone.0063341","volume":"8","author":"SK Pal","year":"2013","unstructured":"Pal SK, Nelson RA, Vogelzang N (2013) Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era. PLoS ONE 8(5):e63341. doi:\n                        10.1371\/journal.pone.0063341","journal-title":"PLoS ONE"},{"issue":"2","key":"1703_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/cam4.574","volume":"5","author":"P Li","year":"2016","unstructured":"Li P, Wong Y-N, Armstrong K et al (2016) Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med 5(2):169\u2013181. doi:\n                        10.1002\/cam4.574","journal-title":"Cancer Med"},{"issue":"2","key":"1703_CR8","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.clgc.2013.09.007","volume":"12","author":"U Vaishampayan","year":"2014","unstructured":"Vaishampayan U, Vankayala H, Vigneau FD et al (2014) The effect of targeted therapy on overall survival in advanced renal cancer: a study of the National Surveillance Epidemiology and End Results Registry Database. Clin Genitourin Cancer 12(2):124\u2013129. doi:\n                        10.1016\/j.clgc.2013.09.007","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"1703_CR9","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.urology.2015.05.008","volume":"86","author":"LC Macleod","year":"2015","unstructured":"Macleod LC, Tykodi SS, Holt SK et al (2015) Trends in metastatic kidney cancer survival from the cytokine to the targeted therapy era. Urology 86(2):262\u2013268. doi:\n                        10.1016\/j.urology.2015.05.008","journal-title":"Urology"},{"key":"1703_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.12.005","author":"SK Pal","year":"2017","unstructured":"Pal SK, Ghate SR, Li N et al (2017) Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: a SEER\u2013Medicare Database Analysis. Clin Genitourin Cancer. doi:\n                        10.1016\/j.clgc.2016.12.005","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"1703_CR11","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.eururo.2009.06.008","volume":"56","author":"M Sun","year":"2009","unstructured":"Sun M, Lughezzani G, Jeldres C et al (2009) A proposal for reclassification of the fuhrman grading system in patients with clear cell renal cell carcinoma. Eur Urol 56(5):775\u2013781. doi:\n                        10.1016\/j.eururo.2009.06.008","journal-title":"Eur Urol"},{"issue":"7","key":"1703_CR12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","volume":"6","author":"SA Fuhrman","year":"1982","unstructured":"Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6(7):655\u2013663","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"1703_CR13","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.athoracsur.2006.11.044","volume":"83","author":"GL Grunkemeier","year":"2007","unstructured":"Grunkemeier GL, Jin R, Eijkemans MJC, Takkenberg JJM (2007) Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg 83(5):1586\u20131592. doi:\n                        10.1016\/j.athoracsur.2006.11.044","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"1703_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.21037\/atm.2016.08.62","volume":"5","author":"Z Zhang","year":"2017","unstructured":"Zhang Z (2017) Survival analysis in the presence of competing risks. Ann Transl Med 5(3):47. doi:\n                        10.21037\/atm.2016.08.62","journal-title":"Ann Transl Med"},{"issue":"9","key":"1703_CR15","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/bmt.2009.359","volume":"45","author":"L Scrucca","year":"2010","unstructured":"Scrucca L, Santucci A, Aversa F (2010) Regression modeling of competing risk using R: an in depth guide for clinicians. Bone Marrow Transplant 45(9):1388\u20131395. doi:\n                        10.1038\/bmt.2009.359","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"1703_CR16","doi-asserted-by":"publisher","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","volume":"27","author":"B Escudier","year":"2009","unstructured":"Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase iii treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312\u20133318. doi:\n                        10.1200\/JCO.2008.19.5511","journal-title":"J Clin Oncol"},{"issue":"22","key":"1703_CR17","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584\u20133590. doi:\n                        10.1200\/JCO.2008.20.1293","journal-title":"J Clin Oncol"},{"issue":"8","key":"1703_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722\u2013731. doi:\n                        10.1056\/NEJMoa1303989","journal-title":"N Engl J Med"},{"issue":"6","key":"1703_CR19","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P et al (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14(6):552\u2013562. doi:\n                        10.1016\/S1470-2045(13)70093-7","journal-title":"Lancet Oncol"},{"issue":"13","key":"1703_CR20","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","volume":"28","author":"B Escudier","year":"2010","unstructured":"Escudier B, Bellmunt J, N\u00e9grier S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144\u20132150. doi:\n                        10.1200\/JCO.2009.26.7849","journal-title":"J Clin Oncol"},{"issue":"18","key":"1703_CR21","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma. Cancer 116(18):4256\u20134265. doi:\n                        10.1002\/cncr.25219","journal-title":"Cancer"},{"issue":"4","key":"1703_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2014.05.010","volume":"67","author":"FE Vera-Badillo","year":"2015","unstructured":"Vera-Badillo FE, Templeton AJ, Duran I et al (2015) Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol 67(4):740\u2013749. doi:\n                        10.1016\/j.eururo.2014.05.010","journal-title":"Eur Urol"},{"issue":"3","key":"1703_CR23","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","volume":"71","author":"S Fern\u00e1ndez-Pello","year":"2017","unstructured":"Fern\u00e1ndez-Pello S, Hofmann F, Tahbaz R et al (2017) A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 71(3):426\u2013436. doi:\n                        10.1016\/j.eururo.2016.11.020","journal-title":"Eur Urol"},{"issue":"11","key":"1703_CR24","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.2006.06.1218","volume":"25","author":"PI Karakiewicz","year":"2007","unstructured":"Karakiewicz PI, Briganti A, Chun FK-H et al (2007) Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 25(11):1316\u20131322. doi:\n                        10.1200\/JCO.2006.06.1218","journal-title":"J Clin Oncol"},{"issue":"5","key":"1703_CR25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/j.1464-410X.2012.11670.x","volume":"112","author":"L Cindolo","year":"2013","unstructured":"Cindolo L, Chiodini P, Brookman-May S et al (2013) Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. BJU Int 112(5):578\u2013584. doi:\n                        10.1111\/j.1464-410X.2012.11670.x","journal-title":"BJU Int"},{"issue":"Suppl 1","key":"1703_CR26","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/01.cad.0000390767.85658.83","volume":"22","author":"P S\u00e1nchez","year":"2011","unstructured":"S\u00e1nchez P, Calvo E, Dur\u00e1n I (2011) Non-clear cell advanced kidney cancer: is there a gold standard? Anticancer Drugs 22(Suppl 1):S9\u201314. doi:\n                        10.1097\/01.cad.0000390767.85658.83","journal-title":"Anticancer Drugs"},{"issue":"1","key":"1703_CR27","doi-asserted-by":"publisher","first-page":"23.e9","DOI":"10.1016\/j.urolonc.2012.08.011","volume":"32","author":"B Shuch","year":"2014","unstructured":"Shuch B, Hofmann JN, Merino MJ et al (2014) Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. Urol Oncol 32(1):23.e9\u201323.e13. doi:\n                        10.1016\/j.urolonc.2012.08.011","journal-title":"Urol Oncol"},{"key":"1703_CR28","unstructured":"Ljungberg B, Albiges L, Bex A et al (2017) EAU guidelines on renal cell carcinoma. \n                        http:\/\/uroweb.org\/wp-content\/uploads\/10-Renal-Cell-Carcinoma_2017_web.pdf\n                        \n                    . Accessed 27 Feb 2017"},{"issue":"34","key":"1703_CR29","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DYC Heng","year":"2009","unstructured":"Heng DYC, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794\u20135799. doi:\n                        10.1200\/JCO.2008.21.4809","journal-title":"J Clin Oncol"},{"issue":"6","key":"1703_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/iju.12004","volume":"20","author":"U Capitanio","year":"2013","unstructured":"Capitanio U, Abdollah F, Matloob R et al (2013) Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: implications for multimodal therapy. Int J Urol 20(6):572\u2013579. doi:\n                        10.1111\/iju.12004","journal-title":"Int J Urol"},{"key":"1703_CR31","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0175","author":"O Abdel-Rahman","year":"2017","unstructured":"Abdel-Rahman O (2017) Clinical correlates and prognostic value of different metastatic sites in metastatic renal cell carcinoma. Future Oncol. doi:\n                        10.2217\/fon-2017-0175","journal-title":"Future Oncol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-017-1703-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1703-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1703-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,2]],"date-time":"2017-11-02T03:54:53Z","timestamp":1509594893000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-017-1703-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,20]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1703"],"URL":"https:\/\/doi.org\/10.1007\/s11255-017-1703-y","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"type":"print","value":"0301-1623"},{"type":"electronic","value":"1573-2584"}],"subject":[],"published":{"date-parts":[[2017,9,20]]}}}